Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 14

1.

Delayed administration of anti-PD-1 antibody reverses immune dysfunction and improves survival during sepsis.

Brahmamdam P, Inoue S, Unsinger J, Chang KC, McDunn JE, Hotchkiss RS.

J Leukoc Biol. 2010 Aug;88(2):233-40. doi: 10.1189/jlb.0110037. Epub 2010 May 18.

PMID:
20483923
2.

Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockade.

Weber J.

Semin Oncol. 2010 Oct;37(5):430-9. doi: 10.1053/j.seminoncol.2010.09.005. Review.

PMID:
21074057
3.

PD-1 and its ligands in T-cell immunity.

Keir ME, Francisco LM, Sharpe AH.

Curr Opin Immunol. 2007 Jun;19(3):309-14. Epub 2007 Apr 12. Review.

PMID:
17433872
4.

[Pathophysiological basis of surgery-linked sepsis].

Vollmar B.

Chirurg. 2011 Mar;82(3):199-207. doi: 10.1007/s00104-010-2010-7. Review. German.

PMID:
21249327
5.

Costimulatory molecule programmed death-1 in the cytotoxic response during chronic hepatitis C.

Larrubia JR, Benito-Martínez S, Miquel J, Calvino M, Sanz-de-Villalobos E, Parra-Cid T.

World J Gastroenterol. 2009 Nov 7;15(41):5129-40. Review.

6.

Clinical development of mAbs to block the PD1 pathway as an immunotherapy for cancer.

Kline J, Gajewski TF.

Curr Opin Investig Drugs. 2010 Dec;11(12):1354-9. Review.

PMID:
21154117
7.

PD-1 and CTLA-4 inhibitory cosignaling pathways in HIV infection and the potential for therapeutic intervention.

Kaufmann DE, Walker BD.

J Immunol. 2009 May 15;182(10):5891-7. doi: 10.4049/jimmunol.0803771. Review.

8.

Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways.

Fife BT, Bluestone JA.

Immunol Rev. 2008 Aug;224:166-82. doi: 10.1111/j.1600-065X.2008.00662.x. Review.

PMID:
18759926
9.

Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach.

Hotchkiss RS, Monneret G, Payen D.

Lancet Infect Dis. 2013 Mar;13(3):260-8. doi: 10.1016/S1473-3099(13)70001-X. Review.

10.

Immunotherapy: A promising approach to reverse sepsis-induced immunosuppression.

Patil NK, Bohannon JK, Sherwood ER.

Pharmacol Res. 2016 Sep;111:688-702. doi: 10.1016/j.phrs.2016.07.019. Epub 2016 Jul 25. Review.

11.

Targeting Immune Cell Checkpoints during Sepsis.

Patil NK, Guo Y, Luan L, Sherwood ER.

Int J Mol Sci. 2017 Nov 14;18(11). pii: E2413. doi: 10.3390/ijms18112413. Review.

12.

The changing immune system in sepsis: is individualized immuno-modulatory therapy the answer?

Boomer JS, Green JM, Hotchkiss RS.

Virulence. 2014 Jan 1;5(1):45-56. doi: 10.4161/viru.26516. Epub 2013 Sep 25. Review.

13.

The pathogenesis of sepsis.

Stearns-Kurosawa DJ, Osuchowski MF, Valentine C, Kurosawa S, Remick DG.

Annu Rev Pathol. 2011;6:19-48. doi: 10.1146/annurev-pathol-011110-130327. Review.

14.

Defining immunological dysfunction in sepsis: A requisite tool for precision medicine.

Bermejo-Martin JF, Andaluz-Ojeda D, Almansa R, Gandía F, Gómez-Herreras JI, Gomez-Sanchez E, Heredia-Rodríguez M, Eiros JM, Kelvin DJ, Tamayo E.

J Infect. 2016 May;72(5):525-36. doi: 10.1016/j.jinf.2016.01.010. Epub 2016 Feb 3. Review.

PMID:
26850357

Supplemental Content

Support Center